NCT05760300 - A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 15, 2023

Primary Completion Date

July 18, 2024

Study Completion Date

July 23, 2024

Conditions

Chronic Hepatitis D Infection

Interventions

DRUG

Bulevirtide (BLV)

Administered via subcutaneous (SC) injections

Trial Locations (9)

Velocity Clinical Research, New Smyrna Beach, Edgewater

Clinical Pharmacology of Miami, LLC, Miami

Panax Clinical Research, Miami Lakes

Floridian Clinical Research, LLC, Miami Lakes

Advanced Pharma CR, LLC, Miami

Genesis Clinical Research, LLC, Tampa

Global Clinical Professionals Research, St. Petersburg

Nucleus Network, Saint Paul

Massachusetts General Hospital - Renal Associates Clinic, Boston